Gene Therapy Analytical Development Europe | Virtual Event

Memo

Gene Therapy Analytical Development Europe is the only digital conference solely dedicated to overcoming the unique analytical challenges encountered in the gene therapy space. With hotly anticipated gene therapy clinical progress in Europe, Gene Therapy Analytical Development Europe will be the industry's definitive conference for gene therapy developers. The agenda has been designed to unite analytical experts to navigate the challenging regulatory landscape and develop robust analytical tools. Following an extremely successful event in Boston, our goal is to deliver an industry-focused virtual event tailored specifically to the analytical challenges facing gene therapy developers, enabling 'boots on the ground' scientists to overcome their challenges to guarantee the consistency, quality and safety of gene therapy products. This is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. URLs:Tickets: https://go.evvnt.com/606022-2?pid=5569 Brochure: https://go.evvnt.com/606022-3?pid=5569  Date and Time: On Tuesday September 01, 2020 at 8:00 am ends Thursday September 03, 2020 at 5:00 pm Prices:Conference Only - Drug Developer Pricing: GBP 1749.00,Conference + 1 Workshop - Drug Developer Pricing: GBP 1998.00,Conference + 2 Workshops -Drug Developer Pricing: GBP 2247.00,Conference + 3 Workshops - Drug Developer Pricing: GBP 2496.00,Conference Only - Vendor Pricing: GBP 2029.00,Conference + 1 Workshop - Vendor Pricing: GBP 2348.00,Conference + 2 Workshops - Vendor Pricing: GBP 2667.00,Conference + 3 Workshops - Vendor Pricing: GBP 2986.00 Speakers: Ales Strancar, Chief Executive Officer BIA Separations, Clare Blue, Director of Analytical Development Biogen, David Dobnik, Scientific Associate, Head of Laboratory for Therapeutic Viruses National Institute of Biology, Debaditya Bhattacharya, Group Leader, Analytical Development bluebird bio, Doyoung Lee, Senior Scientist, Lead UK DRI Vector Core King's College London, Edina Ljubovic-Couteau, Director, Drug Product Development UniQure, Elina Hessels, Senior Scientist, Lead Assay Development UniQure, Eric Yearley, Principal Scientist, Analytical Development BridgeBio, Franz Schnetzinger, Director, Quality Control and Chemical Manufacturing Control Analytical Development Gyroscope, Ian Anderson, Senior Manager, Analytical Sciences Allergan, Jaap Twisk, Senior Director, Analytical Development UniQure, Jennifer Lin, Senior Scientist Orchard Therapeutics, Joseph Lee, Executive Director, Analytical Development PTC Therapeutics, Marina Feschenko, Director, Analytical Development- Gene Therapy/Biologics Biogen, Mark Plavsic, Chief Technology Officer Lysogene, Marthi Pretorius, Analytical Project Lead Novartis, Nathan Weinstock, Senior Scientist, Technical Development, Gene Therapy GMP Interface, Assay Transfer Biogen, Renee Tobias, Director of Marketing Halo Labs, Robert Pletzenauer, Head of Process Analytics Takeda, Sonya Schermann, Director, Analytics Freeline Therapeutics, Sushmita 'Mimi' Roy, Executive Director, Analytical Sciences BioMarin, Tushar Patel, Scientist I, Vector Characterization bluebird bio, Uditha deAlwis, Executive Director Analytical Sciences (AD/QC) Sarepta Therapeutics, Vesselin Mitaksov, Senior Principal Scientist Pfizer, Yuan Zhao, Principal Scientist, Leader of Gene Therapy Section, Advanced Therapy Division/ NIBSC, Medicines and Healthcare Products Regulatory Agency